Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
KAPA
Kairos Pharma, Ltd.
CAPPED RATING
Kairos Pharma, Ltd. (KAPA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
B+
Factor Score
3.7
/ 5.0
Growth
D-
Factor Score
1.0
/ 5.0
Profitability
D
Factor Score
1.4
/ 5.0
Momentum
F
Factor Score
0.4
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.1
EV / EBITDA
0.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-79.8%
Price Return 12M
-92.2%
Catalyst Signal
0.00
Market Cap
$1.7M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-114.0%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B+ (3.7) | D- (1.0) | D (1.4) | F (0.4) | C+ (2.6) | D+ (1.8) |
| 2026-11-05 | A- (3.9) | D- (1.0) | D (1.5) | F (0.4) | C+ (2.7) | C- (1.9) |
| 2026-10-29 | B+ (3.7) | D- (1.0) | D+ (1.7) | F (0.6) | C+ (2.7) | C- (1.9) |
| 2026-10-22 | B+ (3.7) | D- (1.0) | D+ (1.7) | F (0.5) | C+ (2.6) | C- (1.9) |
| 2026-10-15 | B+ (3.7) | D- (1.0) | D+ (1.7) | F (0.7) | C+ (2.6) | C- (1.9) |
Page
1
of
3